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 Background The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer 
Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually 
to provide updates on cancer incidence and death rates and trends in these outcomes for the United States. This 
year’s report includes incidence trends for human papillomavirus (HPV)–associated cancers and HPV vaccination 
(recommended for adolescents aged 11–12 years).
 Methods Data on cancer incidence were obtained from the CDC, NCI, and NAACCR, and data on mortality were obtained 
from the CDC. Long- (1975/1992–2009) and short-term (2000–2009) trends in age-standardized incidence and 
death rates for all cancers combined and for the leading cancers among men and among women were examined 
by joinpoint analysis. Prevalence of HPV vaccination coverage during 2008 and 2010 and of Papanicolaou (Pap) 
testing during 2010 were obtained from national surveys.
 Results Death rates continued to decline for all cancers combined for men and women of all major racial and ethnic 
groups and for most major cancer sites; rates for both sexes combined decreased by 1.5% per year from 2000 
to 2009. Overall incidence rates decreased in men but stabilized in women. Incidence rates increased for two 
HPV-associated cancers (oropharynx, anus) and some cancers not associated with HPV (eg, liver, kidney, thy-
roid). Nationally, 32.0% (95% confidence interval [CI] = 30.3% to 33.6%) of girls aged 13 to 17 years in 2010 had 
received three doses of the HPV vaccine, and coverage was statistically significantly lower among the uninsured 
(14.1%, 95% CI = 9.4% to 20.6%) and in some Southern states (eg, 20.0% in Alabama [95% CI = 13.9% to 27.9%] and 
Mississippi [95% CI = 13.8% to 28.2%]), where cervical cancer rates were highest and recent Pap testing preva-
lence was the lowest.
 Conclusions The overall trends in declining cancer death rates continue. However, increases in incidence rates for some HPV-
associated cancers and low vaccination coverage among adolescents underscore the need for additional preven-
tion efforts for HPV-associated cancers, including efforts to increase vaccination coverage.
  J Natl Cancer Inst;2013;105:175–201
The American Cancer Society (ACS), the Centers for Disease 
Control and Prevention (CDC), the National Cancer Institute 
(NCI), and the North American Association of Central Cancer 
Registries (NAACCR) collaborate annually to provide updated 
cancer incidence and mortality data for the United States. The 
initial report documented the first steady decline in cancer death 
rates, beginning in the early 1990s, since national record keeping 
on vital statistics began in 1930 (1). In addition to providing updates 
on incidence and mortality patterns, each report features a topic of 
special interest (2–14). This report features the burden and trends 
in human papillomavirus (HPV)–associated cancers among persons 
aged 15 years or older and HPV vaccination coverage levels among 
adolescents aged 13 to 17 years.
Exposure to HPV is common through sexual contact, and most 
infections resolve over time. However, persistent infection with 
oncogenic HPV types is etiologically linked to cervical cancer (15), 
as well as cancers of the oropharynx (16), anus (17), vagina and 
vulva (18), and penis (19,20). Virtually all cervical cancers are due 
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to HPV infection, along with 90% of anal cancers, more than 60% 
of certain subsites of oropharyngeal cancers, and 40% of vagina, 
vulva, and penile cancers (20). Although there are approximately a 
dozen oncogenic HPV types, HPV 16 and 18 are the most com-
mon HPV types and are found in approximately 70% of cervical 
cancers. Human papillomavirus 16 is found in approximately 90% 
of the noncervical cancers often associated with HPV infection 
(20). Human papillomavirus types 6 and 11 are associated with 
the development of 90% of anogenital warts (21). Two vaccines 
(bivalent and quadrivalent) are available to protect against HPV 
types 16 and 18. Data from clinical trials have shown that both 
vaccines prevent vaccine type–related cervical precancers (22,23); 
the quadrivalent vaccine has been shown to also prevent vaginal, 
vulvar, and anal precancers (24,25). Although data show the vac-
cines prevent various outcomes, no data are available on the effi-
cacy for prevention of HPV-associated cancers or lesions of the 
oropharynx. Because HPV 16 is responsible for the majority of 
HPV-associated cancers (20), the vaccines likely protect against 
these outcomes. The quadrivalent vaccine also protects against 
HPV 6 and 11, and clinical trials show the vaccine prevents vac-
cine type–related genital warts (26). The Advisory Committee on 
Immunization Practices (ACIP) recommends routine vaccination 
of girls aged 11 or 12 years with three doses of either vaccine and 
routine vaccination of boys aged 11 or 12 years with three doses 
of quadrivalent vaccine (27–29). Vaccination is also recommended 
for women aged 13 through 26 years and men aged 13 through 
21 years who were not vaccinated previously. Men aged 22 through 
26 years may also receive the vaccine. The goals of the current vac-
cination recommendations for adolescents are to prevent persistent 
HPV infections and the occurrence of anogenital warts beginning 
in young adulthood and cervical, vaginal, vulvar, and anal cancers 
that occur later in life. The occurrence of cervical cancer can also 
be prevented through screening (eg, Papanicolaou [Pap] and HPV 
testing) (30–32), and Pap testing has contributed to the substan-
tial declines in cervical cancer rates in the United States and other 
developed countries over the past several decades (33).
Subjects and Methods
New Cancer Cases and Deaths
Population-based data on cancer incidence were based on the 
CDC’s National Program of Cancer Registries (NPCR) and/or 
the NCI’s Surveillance, Epidemiology, and End Results (SEER) 
program that met NAACCR’s data quality criteria (34). Site and 
histology for incident invasive cancers were coded according to the 
International Classification of Diseases for Oncology edition in use 
at the time of diagnosis, converted to the Third Edition coding 
(35), and categorized according to SEER site groups (36). Cancers 
of the oral cavity and pharynx mentioned in the main sections of 
the annual report include all cancers arising at these sites. Incidence 
rates were calculated for all sites combined, childhood cancers (ages 
0–14 and 0–19  years), and the 17 most common cancers among 
men and 18 most common cancers among women to accommodate 
the 15 most common cancers for all races and ethnicities combined 
and for each of the five major racial and ethnic groups (white, black, 
Asian and Pacific Islander [API], American Indian/Alaska Native 
[AI/AN], and Hispanic) by sex. Hispanic ethnicity includes men 
and women from all races identified as Hispanic. Rates for AI/ANs 
were based on cases and deaths occurring in counties covered by 
the Indian Health Service’s Contract Health Service Delivery Area 
because of the high-quality ascertainment of race/ethnicity in these 
areas (10,37).
Incidence data were not available uniformly for every calendar 
year, geographic area, and racial and ethnic group in the United 
States. Therefore, long-term (1992–2009) incidence trends for all 
racial and ethnic groups combined were estimated using data from 
the 13 SEER registries covering approximately 14% of the US 
population (38). Five-year (2005–2009) average annual incidence 
rates and short-term (2000–2009) incidence trends for all racial 
and ethnic groups combined and for each of the five major racial 
and ethnic populations were calculated using combined data from 
NPCR and SEER registries, covering 93% (for the rates) and 87% 
(for the trends) of the US population.
Cause of death was based on death certificate information 
reported to state vital statistics offices and compiled into a national 
file through the CDC National Center for Health Statistics’ 
National Vital Statistics System (39). To maximize comparability 
among International Classification of Diseases and International 
Classification of Diseases for Oncology versions, cause of death 
was categorized according to SEER site groups (36). The underly-
ing causes of death were selected according to the version of the 
International Classification of Diseases codes and selection rules 
in use at the time of death (International Classification of Diseases 
6 to International Classification of Diseases 10). Death rates were 
calculated for all sites combined, childhood cancers, and the 17 
most common cancers among men and 18 most common cancers 
in women in order to include the 15 most common cancers for 
all races and ethnicities combined and for each of the five major 
racial and ethnic groups by sex. We examined long-term (1975–
2009) mortality trends for all racial and ethnic groups combined, 
and 5-year (2005–2009) average annual death rates and short-term 
(2000–2009) mortality trends for all racial and ethnic groups com-
bined and for each of the five major racial and ethnic groups.
For classifying HPV-associated cancers, we used the same 
framework as in a prior study (40), by selecting invasive, 
microscopically confirmed squamous cell carcinomas (histology 
codes 8050–8084 and 8120–8131) of certain subsites of the 
oropharynx (including the base of the tongue, tonsils, and other 
oropharynx), anus (including rectum), vagina, vulva, and penis 
(35,36) in which HPV DNA is frequently found. For cervical 
cancers, all epithelial carcinomas were selected using histology 
codes 8010 to 8671 and 8940 to 8941 because all are considered to 
be HPV associated (15). However, it is noteworthy that information 
about the HPV DNA status of the specific cancers included in 
these analyses was not available and not all of these tumors were 
necessarily HPV positive. In contrast to all ages combined for the 
other sites, analyses of HPV-associated cancers were restricted to 
men and women aged 15 years or older. We present the burden as 
the total number of HPV-associated cancers for the most recent year 
of diagnosis (2009) by sex, and we present average annual incidence 
rates (per 100  000 population) for 2005–2009 by sex, race and 
ethnicity, and area-level socioeconomic status (41). In addition, we 
examined temporal trends in the annual incidence rates for HPV-
associated cancers from 2000 to 2009 by sex and race and ethnicity.
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HPV Vaccination Coverage
Data on HPV vaccination coverage for receipt of one or more 
and three (some received more than three) doses of HPV vaccine 
among girls aged 13 to 17 years for 2008 and 2010 were obtained 
from the National Immunization Survey-Teen (NIS-Teen), a 
random-digit-dialed landline telephone survey of US households 
(42,43). The parents and guardians of eligible adolescents are asked 
during the telephone interview for verbal consent to contact the 
adolescents’ vaccination provider(s). The NIS-Teen uses the list-
assisted method of random-digit-dialed survey, and the sampling 
frame of telephone numbers is updated each quarter to reflect 
new telephone exchanges and area codes (42,43). The NIS-Teen 
is the only national data source to assess provider-verified vaccina-
tion coverage among adolescents. Estimates are reported among 
adolescents aged 13 to 17  years. Measuring at ages 13 through 
17  years allows sufficient time for those who initiated the series 
at age 11 or 12 years to complete it, and it captures information 
on those vaccinated at older ages. Data from this national sur-
vey are weighted based on the sampling design. National esti-
mates are used to monitor coverage as vaccination histories are 
obtained from medical records and sociodemographic information 
is obtained from parents (44). Three-dose series completion rates 
were determined among girls who received at least one dose of 
the HPV vaccine 24 weeks or more before the NIS-Teen interview 
date because administration of the third dose is recommended 24 
weeks after receipt of the first dose. Vaccination coverage estimates 
are presented by demographic characteristics, including by insur-
ance status and Vaccines for Children (VFC) program eligibility. 
The VFC program provides free vaccine to children and adoles-
cents through 18 years of age who are uninsured, eligible for the 
Medicaid program, American Indian or Alaska Native, or underin-
sured. Underinsured children (whose insurance does not cover vac-
cine) are eligible to receive VFC vaccine only through a federally 
qualified health center or rural health clinic (45).
Prevalence of Pap Testing
Data from the 2010 Behavioral Risk Factor Surveillance System 
(BRFSS), a state-based, random-digit-dialed telephone survey, 
were used to estimate the state-level (and national average) preva-
lence of recent Pap testing (during the previous 3 years) for women 
aged 21 to 65  years with an intact uterus, overall, and by usual 
source of medical care (46). Verbal consent is obtained during the 
interview from survey participants.
Population Estimates
Population estimates from the Census Bureau’s Vintage 2009 
National Tables were used in the SEER*Stat software (http://seer.
cancer.gov/seerstat) to produce mortality and incidence rates by 
age, sex, race, and ethnicity at the county level (38,47). Because the 
Census, beginning in 2000, allowed for selection of multiple races, 
mortality and incidence data by race (ie, the numerators for death 
and incidence rates) are not wholly compatible with the popula-
tion data collected in the Census. Therefore, bridged single-race 
estimates were produced by the Census Bureau in collaboration 
with the National Center for Health Statistics (48). For most states, 
population estimates as of July 1 of each year were used to calcu-
late annual incidence rates because these estimates are presumed 
to reflect the average population of a defined geographic area for 
a calendar year. However, certain county population estimates 
were adjusted to account for populations displaced along the Gulf 
Coast of Louisiana, Alabama, Mississippi, and Texas during 2005 by 
Hurricanes Katrina and Rita (38). National total population esti-
mates were not affected by these adjustments. Other specific modi-
fications included using additional local information to estimate 
the native Hawaiian population accurately and to derive popula-
tion estimates for a newly created county in Colorado (38). These 
modified county-level population estimates, summed to the state 
and national level, were used as denominators in rate calculations. 
Population estimates were grouped into three categories according 
to the percent of the population in the county living below the fed-
erally defined poverty threshold: less than 10%, 10.0% to 19.99%, 
and 20% or greater, with the last group considered a severely dis-
advantaged area (41).
Statistical Methods
Incidence and Death Rates and Trends. Average annual cancer 
incidence and death rates per 100 000 persons were age standard-
ized to the 2000 US standard population by the direct method 
(49). Corresponding 95% confidence intervals (CIs) were calcu-
lated as modified gamma intervals (50). For stability and reliabil-
ity, rates were not reported if the numerator included less than 16 
observations.
Trends in age-standardized cancer incidence and death rates 
were analyzed using joinpoint regression, which involves fitting a 
series of joined straight lines on a logarithmic scale to the trends 
in the annual age-standardized rates (http://www.srab.cancer.gov/
joinpoint) (51) with at least three data points between changes in 
joinpoints. Up to three joinpoints were allowed in models for the 
period 1992 to 2009, up to five joinpoints were allowed in mod-
els for the period 1975 to 2009, and up to two joinpoints were 
allowed in models for the period 2000 to 2009. The number of 
joinpoints is constrained by the number of intervals available to 
identify the years in which there was a statistically significant 
change in the trends. The resulting trends of varying time periods 
were described by the slope of the line segment or annual percent-
age change (APC). The average annual percentage change (AAPC) 
was estimated as a geometric weighted average of the APCs, with 
the weights equal to the length of each line segment during the 
prespecified fixed interval (eg, 2000–2009) (http://srab.cancer.
gov/joinpoint/aapc.html) (52). Long-term incidence trends were 
calculated using both observed and delay-adjusted SEER 13 data; 
however, descriptions of these trends were based on the delay-
adjusted data, except when noted. Delay adjustment is a statistical 
method to correct for unreported (delayed) or updated cases and 
mostly affects cancers diagnosed in recent years and cancers diag-
nosed in nonhospital settings (eg, melanoma or leukemia) (53). 
Delay-adjusted rates include two sources of variability. The first is 
the usual variability of the rates themselves, and the second is the 
variability from the delay model, which includes the uncertainty of 
the delay adjustments. The delay-adjustment method is not avail-
able for NPCR areas. Therefore, short-term trends (2000–2009) 
by race and ethnicity were based on observed NPCR and SEER 
combined data. We used the t test and the Z test, respectively, to 
assess whether the APC and the AAPC were statistically different 
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from zero; all statistical tests were two-sided. In describing trends, 
the terms “increase” or “decrease” were used when the slope (APC 
or AAPC) of the trend was statistically significant (P < .05). For 
non-statistically significant trends, terms such as “stable,” “non-
significant increase,” and “nonsignificant decrease” were used. 
Incidence rates of HPV-associated cancers by area-level socioeco-
nomic status were considered to be statistically significantly differ-
ent if the 95% confidence intervals for the groups being compared 
did not overlap.
HPV Vaccination Coverage Levels. Sample-weighted national vac-
cination coverage estimates, as well as the percentage point changes 
in estimates from 2008 to 2010, for selected sociodemographic 
characteristics and by state were calculated using Statistical Analysis 
Software (SAS, version 9.3, SAS Institute, Cary, NC)–callable- 
SUDAAN (release 10.0, Research Triangle Institute, Research 
Triangle Park, NC) (54). The two-sided t test was used to determine 
whether overall differences in vaccination estimate percentage point 
changes from 2008 to 2010 were statistically significant (P < .05). 
Differences in vaccination coverage estimates by sociodemographic 
characteristics were considered to be statistically different if the 95% 
confidence intervals for the groups being compared did not overlap. 
State-level coverage estimates are displayed by their overall quartile 
distribution. State-level vaccination coverage estimates were consid-
ered to be statistically significantly different from the national esti-
mate if their 95% confidence intervals did not overlap.
Prevalence of Pap Testing. SAS-callable-SUDAAN (54) was 
used to calculate national and state-level weighted prevalence esti-
mates of recent Pap testing and corresponding 95% confidence 
intervals, taking into account the complex survey design of the 
BRFSS. The relationships between state-level HPV vaccination 
coverage and Pap testing prevalence and between cervical cancer 
incidence rates and Pap testing prevalence were assessed with the 
Pearson correlation coefficient (r, weighted by the inverse of the 
variance of Pap testing prevalence). The correlation coefficients 
were calculated in SAS, and a two-sided t test was used to assess 
statistical significance (P < .05).
results
Long-Term (1992–2009) Cancer Incidence Trends  
for All Racial and Ethnic Groups Combined
Trend analysis based on SEER 13 data showed that overall delay-
adjusted cancer incidence rates in all racial and ethnic groups and 
sexes combined were stable from 2000 to 2009 (Table 1). Among 
men, overall cancer incidence decreased on average by 0.6% annu-
ally from 1994 to 2009. Overall cancer incidence rates among 
women decreased 0.5% annually from 1998 to 2006, but rates were 
stable from 2006 to 2009. Overall cancer incidence rates increased 
by 0.6% per year among children aged 0 to 14 years and by 0.7% 
per year among children aged 0 to 19 years from 2000 to 2009, 
continuing trends from 1992.
Among men, incidence rates from 2000 to 2009 decreased for 
five of the 17 most common cancers: prostate, lung and bronchus 
(lung), colon and rectum (colorectal), stomach, and larynx. In con-
trast, rates among men during the same time interval increased for 
six cancers: kidney and renal pelvis (kidney), pancreas, liver and 
intrahepatic bile duct (liver), thyroid, melanoma of the skin (mela-
noma), and myeloma. Among women, incidence rates decreased 
from 2000 to 2009 for seven of the 18 most common cancers: lung, 
colorectal, urinary bladder (bladder), cervix uteri (cervix), oral cav-
ity and pharynx (all tumors regardless of their potential association 
with HPV infection), ovary, and stomach. Incidence rates among 
women increased from 2000 to 2009 for seven cancers: thyroid, 
melanoma, kidney, pancreas, leukemia, liver, and corpus and uterus 
(uterus). Incidence rates were stable for all other cancers during 
the period from 2000 to 2009, including female breast cancer and 
non-Hodgkin lymphoma in men and women.
Long-Term (1975–2009) Cancer Mortality Trends  
for All Racial and Ethnic Groups Combined
Overall cancer death rates have been declining since the early 
1990s, with rates decreasing by about 1.8% per year in men and 
by 1.4% per year in women from 2000 to 2009 (Table 2). Among 
children, rates have continued to decrease since 1975, although the 
decrease was briefly interrupted from 1998 to 2003. During the 
period from 2000 to 2009 and the period from 2005 to 2009, death 
rates among men decreased for 10 of the 17 most common cancers 
(lung, prostate, colorectal, leukemia, non-Hodgkin’s lymphoma, 
kidney, stomach, myeloma, oral cavity and pharynx, and larynx), 
whereas rates increased for cancers of the pancreas, liver, and mela-
noma of the skin. During the same time periods, death rates among 
women decreased for 15 of the 18 most common cancers (lung, 
breast, colorectal, ovary, leukemia, non-Hodgkin lymphoma, brain 
and central nervous system, myeloma, kidney, stomach, cervix, blad-
der, esophagus, oral cavity and pharynx, and gallbladder), whereas 
they increased for cancers of the pancreas, liver, and uterus.
Cancer Incidence Rates (2005–2009) and Short-Term 
(2000–2009) Trends by Race and Ethnicity
Five-year incidence rates (2005–2009) and short-term trends 
(2000–2009), which were not delay adjusted, are presented for men 
and women by race and ethnicity in Table 3. For all cancer sites 
combined and all racial and ethnic groups, cancer incidence rates 
for the period from 2005 to 2009 were higher among men than 
women. Black men had the highest overall cancer incidence rate 
of any racial and ethnic group. Among men, the highest incidence 
rates were observed for prostate cancer, followed by lung and colo-
rectal cancer in each racial and ethnic group, except for Hispanics, 
in whom colorectal cancer ranked second. Among women, the 
highest overall incidence rates during the period from 2005 to 
2009 were in whites followed by blacks. Generally, breast cancer 
had the highest incidence rate, followed by lung and colorectal can-
cers, except among API and Hispanic women, in whom colorectal 
cancer was more common than lung cancer. Uterine cancer ranked 
fourth among women of each racial and ethnic group except API 
women, in whom thyroid cancer was the fourth most common can-
cer. Beyond the three most commonly diagnosed cancers for men 
and four most commonly diagnosed cancers for women, cancer 
ranking varied by race and ethnicity.
During the period from 2000 to 2009, incidence rates for all can-
cers combined declined among men of each racial and ethnic group, 
although the decrease was not statistically significant for AI/AN men. 
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(Table continues)
Table 1. Surveillance, Epidemiology, and End Results (SEER) cancer incidence rate trends with joinpoint analyses from 1992 to 2009 for 
the most common cancers, by sex, for all racial and ethnic groups combined*
Joinpoint analyses (1992–2009)†
Trend 1 Trend 2 Trend 3 Trend 4 AAPC‡
Cancer site or type  
by sex Years APC§ Years APC§ Years APC§ Years APC§ 2000–2009 2005–2009
All sites||
 Both sexes 1992–1994 −3.1¶ 1994–1999 0.3 1999–2009 −0.6¶ −0.6# −0.6#
  Delay adjusted 1992–1994 −3.1¶ 1994–1999 0.4 1999–2005 −0.7¶ 2005–2009 0.1 −0.4 0.1
 Men 1992–1995 −4.5¶ 1995–2000 0.2 2000–2009 −1.0¶ −1.0# −1.0#
  Delay adjusted 1992–1994 −5.6¶ 1994–2009 −0.6¶ −0.6# −0.6#
 Women 1992–1994 −0.4 1994–1998 1.2 1998–2004 −0.8¶ 2004–2009 0.2 −0.2 0.2
  Delay adjusted 1992–1998 0.8¶ 1998–2006 −0.5¶ 2006–2009 1.0 0.0 0.6
 Children (ages 0–14) 1992–2009 0.5¶ 0.5# 0.5#
  Delay adjusted 1992–2009 0.6¶ 0.6# 0.6#
 Children (ages 0–19) 1992–2009 0.6¶ 0.6# 0.6#
  Delay adjusted 1992–2009 0.7¶ 0.7# 0.7#
17 most common  
cancers for men**
 Prostate 1992–1995 −11.2¶ 1995–2000 2.1 2000–2009 −2.1¶ −2.1# −2.1#
  Delay adjusted 1992–1995 −11.1¶ 1995–2000 2.0 2000–2009 −1.9¶ −1.9# −1.9#
 Lung and bronchus 1992–2009 −2.0¶ −2.0# −2.0#
  Delay adjusted 1992–2009 −1.9¶ −1.9# −1.9#
 Colon and rectum 1992–1995 −2.6¶ 1995–1998 1.6 1998–2009 −2.7¶ −2.7# −2.7#
  Delay adjusted 1992–1995 −2.6¶ 1995–1998 1.5 1998–2009 −2.6¶ −2.6# −2.6#
 Urinary bladder 1992–2007 0.1 2007–2009 −3.3 −0.7 −1.6
  Delay adjusted 1992–2007 0.1 2007–2009 −2.5 −0.5 −1.2
 Melanoma of the skin 1992–2009 2.4¶ 2.4# 2.4#
  Delay adjusted 1992–2009 2.5¶ 2.5# 2.5#
Non-Hodgkin  
lymphoma
1992–2009 0.1 0.1 0.1
  Delay adjusted 1992–2009 0.2 0.2 0.2
 Kidney and renal pelvis 1992–2009 2.3¶ 2.3# 2.3#
  Delay adjusted 1992–1999 1.3¶ 1999–2009 2.9¶ 2.9# 2.9#
Oral cavity and  
pharynx
1992–2005 −1.4¶ 2005–2009 1.5 −0.1 1.5
  Delay adjusted 1992–2005 −1.4¶ 2005–2009 1.8 0.0 1.8
 Leukemia 1992–2009 −0.3¶ −0.3# −0.3#
  Delay adjusted 1992–2009 0.2 0.2 0.2
 Pancreas 1992–2002 0.0 2002–2009 1.4¶ 1.1# 1.4#
  Delay adjusted 1992–2002 0.0 2002–2009 1.7¶ 1.3# 1.7#
Liver and intrahepatic  
bile duct
1992–2009 3.5¶ 3.5# 3.5#
  Delay adjusted 1992–2009 3.7¶ 3.7# 3.7#
 Stomach 1992–2009 −1.7¶ −1.7# −1.7#
  Delay adjusted 1992–2009 −1.7¶ −1.7# −1.7#
 Esophagus 1992–2009 0.0 0.0 0.0
  Delay adjusted 1992–2009 0.0 0.0 0.0
Brain and other  
nervous system
1992–2009 −0.3¶ −0.3# −0.3#
  Delay adjusted 1992–2009 −0.2 −0.2 −0.2
 Myeloma 1992–2009 0.2 0.2 0.2
  Delay adjusted 1992–2009 0.5¶ 0.5# 0.5#
 Larynx 1992–2009 −2.8¶ −2.8# −2.8#
  Delay adjusted 1992–2009 −2.8¶ −2.8# −2.8#
 Thyroid 1992–1996 −1.4 1996–2009 5.5¶ 5.5# 5.5#
  Delay adjusted 1992–1996 −1.4 1996–2009 5.6¶ 5.6# 5.6#
18 most common  
cancers for women**
 Breast 1992–1999 1.3¶ 1999–2005 −2.0¶ 2005–2009 0.9 −0.7 0.9
  Delay adjusted 1992–1999 1.3¶ 1999–2005 −2.0¶ 2005–2009 1.1 −0.6 1.1
 Lung and bronchus 1992–1998 0.8¶ 1998–2001 −1.3 2001–2005 0.5 2005–2009 −1.2¶ −0.5 −1.2#
  Delay adjusted 1992–1997 0.7 1997–2009 −0.3¶ −0.3# −0.3#
 Colon and rectum 1992–1995 −1.9¶ 1995–1998 1.9 1998–2009 −2.1¶ −2.1# −2.1#
  Delay adjusted 1992–1995 −1.8¶ 1995–1998 1.9 1998–2009 −2.1¶ −2.1# −2.1#
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In contrast, rates of all cancers combined among women decreased 
only in whites and Hispanics. Childhood cancer incidence rates 
among those aged 0 to 19 years increased for black and Hispanic chil-
dren but were stable for children of all other racial and ethnic groups; 
however, blacks had the lowest rates of any racial and ethnic group. 
Prostate cancer incidence rates declined among men of all racial and 
ethnic groups. Breast cancer incidence rates declined during the 
period from 2000 to 2009 among white women but increased among 
black and API women and were stable among AI/AN and among 
Hispanic women; however, in the most recent 5-year period (2005–
2009), rates were stable among women of all racial and ethnic groups. 
Lung cancer incidence rates from 2000 to 2009 declined in men and 
were stable among women of all racial and ethnic groups, although 
rates decreased among all women from 2005 to 2009. Colorectal 
Joinpoint analyses (1992–2009)†
Trend 1 Trend 2 Trend 3 Trend 4 AAPC‡
Cancer site or type  
by sex Years APC§ Years APC§ Years APC§ Years APC§ 2000–2009 2005–2009
 Corpus and uterus, NOS 1992–2006 −0.2 2006–2009 3.1¶ 0.9# 2.3#
  Delay adjusted 1992–2007 −0.1 2007–2009 5.2¶ 1.0# 2.5#
 Thyroid 1992–1999 4.1¶ 1999–2009 6.9¶ 6.9# 6.9#
  Delay adjusted 1992–1999 4.1¶ 1999–2009 7.0¶ 7.0# 7.0#
 Non-Hodgkin lymphoma 1992–2003 1.3¶ 2003–2009 −0.5 0.1 −0.5
  Delay adjusted 1992–2003 1.4¶ 2003–2009 −0.1 0.4 −0.1
 Melanoma of the skin 1992–1997 4.0¶ 1997–2009 1.6¶ 1.6# 1.6#
  Delay adjusted 1992–1997 3.9¶ 1997–2009 1.7¶ 1.7# 1.7#
 Ovary|| 1992–2001 −0.6¶ 2001–2009 −1.4¶ −1.3# −1.4#
  Delay adjusted|| 1992–2009 −0.9¶ −0.9# −0.9#
 Kidney and renal pelvis 1992–2009 2.5¶ 2.5# 2.5#
  Delay adjusted 1992–1998 1.3 1998–2009 3.1¶ 3.1# 3.1#
 Pancreas 1992–2009 0.6¶ 0.6# 0.6#
  Delay adjusted 1992–2000 −0.1 2000–2009 1.4¶ 1.4# 1.4#
 Leukemia 1992–2009 0.0 0.0 0.0
  Delay adjusted 1992–2009 0.5¶ 0.5# 0.5#
 Urinary bladder 1992–2004 −0.2 2004–2009 −1.7¶ −1.0# −1.7#
  Delay adjusted 1992–2004 −0.1 2004–2009 −1.3¶ −0.8# −1.3#
 Cervix uteri 1992–2009 −2.6¶ −2.6# −2.6#
  Delay adjusted 1992–2009 −2.5¶ −2.5# −2.5#
 Oral cavity and pharynx 1992–2009 −1.0¶ −1.0# −1.0#
  Delay adjusted 1992–2009 −0.9¶ −0.9# −0.9#
Brain and other  
nervous system
1992–2009 −0.2 −0.2 −0.2
  Delay adjusted 1992–2009 0.0 0.0 0.0
 Myeloma 1992–2009 −0.1 −0.1 −0.1
  Delay adjusted 1992–2009 0.3 0.3 0.3
 Stomach 1992–2009 −0.8¶ −0.8# −0.8#
  Delay adjusted 1992–2009 −0.8¶ −0.8# −0.8#
Liver and intrahepatic  
bile duct
1992–2009 2.8¶ 2.8# 2.8#
  Delay adjusted 1992–2009 3.0¶ 3.0# 3.0#
* Source: Surveillance, Epidemiology, and End Results (SEER) 13 areas covering about 14% of the US population (Connecticut, Hawaii, Iowa, Utah, and New 
Mexico, the Alaska Native Tumor Registry, rural Georgia, and the metropolitan areas of San Francisco, Los Angeles, San Jose-Monterey, Detroit, Atlanta, and 
Seattle-Puget Sound). AAPC = average annual percent change; APC = annual percent change; NOS = not otherwise specified.
†  Joinpoint analyses with up to three joinpoints yielding up to four trend segments (Trends 1–4) were based on rates per 100 000 persons and were age adjusted to 
the 2000 US standard population (19 age groups: ages <1 year, 1–4 years, 5–9 years, … , 80–84 years, ≥85 years; Census publication p25-1130; US Bureau of the 
Census, Current Population Reports. Washington, DC: US Government Printing Office, 2000). For joinpoint analysis, the Joinpoint Regression Program was used 
(version 3.5.1, July 2011; Surveillance Research Program, National Cancer Institute, Bethesda, MD).
‡ The AAPC is a weighted average of the APCs that is calculated by joinpoint regression.
§ The APC is based on age-adjusted rates (see above).
|| All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
¶ The APC is statistically significantly different from zero (2-sided t test; P < .05).
# The AAPC is statistically significantly different from zero (2-sided Z test; P < .05).
** Cancers are listed in descending rank order of sex-specific, age-adjusted incidence rates for 2005 through 2009 for all racial and ethnic groups combined (using 
data from the National Program of Cancer Registries [NPCR] and SEER Program areas reported by the North American Association of Central Cancer Registries 
[NAACCR] as meeting high-quality incidence data standards for 2005–2009). To include the 15 most common cancers in each racial and ethnic group, more than 
15 cancers are given for men and women in total.
Table 1 (Continued).
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cancer incidence rates from 2000 to 2009 decreased among both 
men and women of every racial and ethnic group, although this 
decrease was not statistically significant for AI/AN men or women. 
Liver cancer incidence rates increased among white, black, AI/AN, 
and Hispanic men and among white, black, and Hispanic women. 
Pancreas cancer incidence rates increased only among white men and 
women and black men. Kidney and thyroid cancer incidence rates 
increased among men and women of every racial and ethnic group, 
except the thyroid cancer incidence rate did not increase among AI/
AN men. Uterine cancer incidence rates increased among women of 
all racial and ethnic groups, although increases were not statistically 
significant among white and AI/AN women.
Current Cancer Death Rates (2005–2009) and Short-Term 
(2000–2009) Trends by Race and Ethnicity
For individuals of all racial and ethnic groups, overall cancer death 
rates declined during the most recent 10-year time period (2000–
2009) among both sexes combined (1.5% per year) and among 
children aged 0 to 19 years (2.0% per year), although the decreases 
were not statistically significant among AI/AN persons (Table 4). 
Similarly, death rates for the most common cancers (lung, colo-
rectal, and prostate) among men decreased in all racial and eth-
nic groups, except among AI/AN men, in whom the decreases 
for lung and colorectal cancers were not statistically significant. 
Among women, death rates for lung, breast and colorectal can-
cers decreased in all racial and ethnic groups, except among AI/
AN women for all three cancers and among API women for lung 
cancer. Death rates increased for liver cancer in white, black, and 
Hispanic men and among white and Hispanic women, whereas 
rates decreased among API men and women. Pancreatic cancer 
death rates increased among white men and women and API men, 
whereas they were stable among the other population subgroups. 
Melanoma death rates increased only among white men.
HPV-Associated Cancer Incidence Rates (2005–2009) and 
Short-Term (2000–2009) Trends
HPV-associated cancers accounted for 3.3% (21 342 of 646 684) of 
all cancer cases among women and 2.0% (13 446 of 676 672) of the 
total cancer cases among men diagnosed in 2009 in the combined 
SEER and NPCR databases (Figure 1). Cervical cancer alone repre-
sents 53.4% of the total number of HPV-associated cancers among 
women and 32.7% of all HPV-associated cancers. Oropharyngeal 
cancer accounts for 78.2% of HPV-associated cancers among men, 
11.6% of HPV-associated cancers among women, and 37.3% of 
HPV-associated cancers among men and women combined.
Incidence rates for HPV-associated oropharyngeal cancers 
(2005–2009) were highest among white and black men (Figure 2). 
Among women, the highest incidence rates occurred among blacks 
and whites for oropharyngeal cancers, among whites for anal 
and vulvar cancers, among blacks for vaginal cancer, and among 
Hispanics for cervical cancer. Anal cancer incidence rates were high-
est among black men. API men and women demonstrated the low-
est incidence rates for each of the HPV-associated cancers, except 
for vaginal cancer, which was lowest among AI/AN women. Cervical 
cancer rates were markedly elevated among most women living in 
low vs high socioeconomic status areas (Table 5), and similar dispar-
ities were noted among men for HPV-associated cancers of the anus 
and penis. No striking socioeconomic status disparities were appar-
ent for the other HPV-associated cancers among men or women.
From 2000 to 2009, incidence rates increased for HPV-
associated cancer of the oropharynx among white men and women, 
for anal cancer among white and black men and women, and for 
cancer of the vulva among white and black women (Figure 3). By 
age, the increases in incidence rates for these cancers were gener-
ally larger among persons aged 55 to 64 years than among younger 
or older individuals (data not shown). In contrast, cervical cancer 
incidence rates decreased for women in all racial and ethnic groups, 
except AI/AN women. Vaginal cancer incidence decreased among 
black women. Rates remained unchanged for penile cancer among 
men in all racial and ethnic groups.
HPV Vaccination Coverage Levels and Prevalence of 
Pap Testing by State, Race and Ethnicity, and Other 
Sociodemographic Factors
Nationally, less than half (48.7%, 95% CI = 46.9% to 50.5%) of 
adolescent girls aged 13 to 17 years in 2010 had received or more 
doses, and 32.0% (95% CI = 30.3% to 33.6%) had received three 
doses of the HPV vaccine (Table 6; Figure 4). Of the girls who ini-
tiated the series (≥1 dose) and had at least 24 weeks between their 
first dose and their NIS-Teen interview date, more than two-thirds 
(69.6%, 95% CI  =  66.8% to 72.2%) completed the three-dose 
series. State-level HPV vaccination coverage levels varied widely in 
2010, ranging from 28.8% (95% CI = 21.6% to 37.3%) in Idaho to 
73.0% (95% CI = 64.6% to 80.0%) in Rhode Island for one or more 
doses, from 17.6% (95% CI = 11.8% to 25.4%) in Idaho to 55.1% 
(95% CI = 46.0% to 63.9%) in Rhode Island for three doses, and 
from 47.4% (95% CI = 34.3% to 60.9%) in Alabama to 87.1% (95% 
CI = 77.1 to 93.1%) in New Hampshire for three-dose series com-
pletion, with coverage in many states being statistically significantly 
lower than the national estimate (Supplementary Table 2, available 
online). In 2010, three-dose coverage was statistically significantly 
lower in some Southern states (eg, 20.0% in both Alabama [95% 
CI = 13.9% to 27.9%] and Mississippi [95% CI = 13.8% to 28.2%]) 
compared with the national coverage level of 32.0% (Supplementary 
Table 2, available online). Between 2008 and 2010, overall initiation 
of the HPV vaccination series statistically significantly increased by 
11.5 (95% CI = 8.7 to 14.3) percentage points, and receipt of three 
doses increased by 14.1 (95% CI = 11.8 to 16.4) percentage points 
nationally (Supplementary Table  1, available online). Vaccination 
coverage rates for one or more doses and three doses increased in 
most states between 2008 and 2010.
Virtually all sociodemographic groups showed statistically 
significant increases in one or more–dose and three-dose cover-
age and series completion rates for HPV vaccination from 2008 
to 2010 (P < .05), although not all the increases were statistically 
significant (Table  6). In 2010, HPV vaccination coverage with 
one or more doses and three doses, as well as series completion, 
increased with age (Table 6). Hispanics (56.2%, 95% CI = 50.6% 
to 61.6%) were statistically significantly more likely than non-His-
panic whites (45.8%, 95% CI = 43.8% to 47.9%) to have received 
one or more HPV vaccine doses by 2010. Girls who were VFC-
eligible and insured (55.7%, 95% CI = 51.6% to 59.8%) were sta-
tistically significantly more likely than privately insured (47.7%, 
95% CI = 45.7% to 49.8%) and VFC-eligible and uninsured girls 
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(34.9%, 95% CI = 26.7% to 44.2%) to have received one or more 
HPV vaccine doses by 2010. Girls who were VFC-eligible and 
uninsured (14.1%, 95% CI =  9.4% to 20.6%) were also signifi-
cantly less likely than privately insured (33.8%, 95% CI = 32.0% 
to 35.7%) girls to have received 3 doses of HPV vaccine by 2010. 
Among girls who initiated the series, Hispanics (56.1%, 95% 
CI = 48.5% to 63.5%) were statistically significantly less likely than 
non-Hispanic whites (74.7%, 95% CI = 71.6% to 77.5%), those 
living below the poverty level (57.3%, 95% CI = 50.1% to 64.2%) 
were statistically significantly less likely than those living above the 
poverty level (73.2%, 95% CI = 70.3% to 76.0%), and the privately 
insured (75.2, 95% CI  =  72.4% to 77.9%) were statistically sig-
nificantly more likely than VFC-eligible and insured girls (60.2%, 
95% CI = 54.1% to 66.1%) and VFC-eligible and uninsured girls 
(41.5%, 95% CI = 27.9% to 56.6%) to complete the three-dose 
series by 2010.
Nationally, 86.7% (95% CI = 86.3% to 87.0%) of women aged 
21 to 65 years had a recent Pap test (during the previous 3 years) in 
2010 (Supplementary Table 2, available online). The prevalence of 
Pap testing varied by state, ranging from 80.2% (95% CI = 76.0% 
to 83.8%) in Arkansas to 93.0% (95% CI = 91.8% to 94.1%) in 
Massachusetts (where cervical cancer rates were low) (Figure  5). 
The prevalence of Pap testing was positively correlated with vac-
cination coverage levels (r = 0.47, P < .01) (Figure 5) but negatively 
correlated with cervical cancer incidence rates (r = −0.41, P < .01). 
State-specific Pap test prevalence was generally low among 
women with no usual source of medical care or health insurance 
(Supplementary Table 2, available online).
Discussion
Overall cancer death rates continue to decrease in the United States, 
and this favorable trend involved men and women, all major racial 
and ethnic groups, and all four major sites, including lung, colorec-
tal, female breast, and prostate cancers. However, death rates con-
tinued to increase for cancers of the liver, pancreas, melanoma (men 
only), and uterus. Similarly, incidence rates continued to increase 
for these cancers and other cancers, including some associated with 
HPV infection (ie, oropharynx and anus). Notably, HPV vaccina-
tion coverage among girls in 2010 remained low, underscoring the 
need for broader interventions to increase vaccination uptake.
Factors that contribute to the favorable trends for lung, colo-
rectal, female breast, and prostate cancer death rates have been 
discussed in previous annual reports and include reductions in 
important risk factors (eg, smoking for lung cancer) and improved 
early detection and treatment (eg, screening as well as adjuvant 
chemotherapy for breast and colorectal cancers) (2–14). In contrast, 
reasons for the increasing death rates for pancreatic and liver can-
cers in men and women, melanoma in men, and uterine cancer in 
women have not been fully elucidated. However, the trends may, 
in part, reflect a high prevalence of chronic hepatitis C virus infec-
tion due to injection drug use during the period from the 1960s 
to the 1980s for liver cancer (55), increased obesity prevalence for 
liver, pancreatic, and uterine cancers (14), and increased harmful 
ultraviolent radiation exposure for melanoma (56). Corresponding 
increases in incidence rates have been noted for all of these four 
cancers (57). Additional cancers with increasing incidence trends 
include thyroid and kidney cancers. Although some studies sug-
gest that the increase in thyroid cancer rates are largely because of 
increased detection of small and indolent tumors by imaging (57–
59), others suggest that unidentified risk factors may also be impor-
tant because rates increased for both small and large tumors (60,61). 
Similarly, the increase in kidney cancer incidence rates is thought to 
reflect, in part, increased diagnosis because of wider application of 
imaging techniques (62) as well as the obesity epidemic (14).
Figure 1. Number of new human papillomavirus (HPV)–associated can-
cers overall, and by sex, in the United States, 2009. Source: National 
Program of Cancer Registries and Surveillance, Epidemiology, and End 
Results areas reported by the North American Association of Central 
Cancer Registries as meeting high-quality incidence data standards for 
the specified time period. Note that the number of cancer cases under-
estimates the actual number of cases occurring because of incomplete 
coverage of population-based registries in 2009 (93%). HPV-associated 
cancers are defined as cancers at specific anatomic sites and with spe-
cific cellular types in which HPV DNA frequently is found. Some of these 
cancers may not necessarily be HPV-positive because no testing was con-
ducted. Virtually all cervical cancers are due to HPV infection, along with 
90% of anal cancers, more than 60% of certain subsites of oropharyngeal 
cancers, and approximately 40% of vagina, vulva, and penile cancers.
JNCI | Articles 189jnci.oxfordjournals.org
Although overall breast cancer incidence rates stabilized dur-
ing the most recent time period (2005–2009) after sharply decreas-
ing between 2002 and 2003 because of reductions in the use of 
postmenopausal hormone replacement therapy (63,64), during the 
period from 2000 to 2009 incidence rates increased among black 
and API women. In addition to reproductive factors and post-
menopausal hormone replacement therapy, obesity after meno-
pause, weight gain throughout life, and alcohol consumption are 
also known risk factors for breast cancer (65). Mammography also 
increases breast cancer incidence rates by detecting tumors at an 
earlier time and detecting indolent cases (66). Whereas the obe-
sity epidemic involved women of all races and ethnicities (67), 
recent increases in mammography are confined to API women 
(68). However, the extent to which these factors contributed to 
the increasing breast cancer incidence rates among black and API 
women is unclear.
With respect to HPV-associated cancers, rates increased for 
cancer of the oropharynx in white men and women, for vulvar can-
cer in white and black women, and for anal cancer in white and 
black men and women. Based on data from three SEER registries, 
the presence of HPV DNA detected in oropharyngeal tumors 
increased from 16.3% during the period from 1984 to 1989 to 
71.7% during the period from 2000 to 2004 (69). The increasing 
trend for HPV-associated oropharyngeal cancer rates is in stark 
contrast with the overall decreasing trend for tobacco-related 
oropharyngeal cancers, largely because of declines in cigarette 
smoking (70). Increases in rates of HPV-associated oropharyngeal 
cancers have also been reported in Canada and several European 
Figure 2. Age-adjusted incidence rates for human papillomavirus (HPV)–
associated cancers in the United States by sex and race and ethnicity, 
2005 to 2009. The scale of the y axis differs for cervical cancer. The rates 
for the period from 2005 to 2009 for the five major racial and ethnic 
groups are from 47 states: Alabama, Alaska, Arizona, California, Colorado, 
Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, 
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, 
Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, 
Nevada, New Hampshire, New Jersey, New Mexico, New York, North 
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode 
Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, 
Washington, West Virginia, Wyoming. Source: National Program of 
Cancer Registries and Surveillance, Epidemiology, and End Results areas 
reported by the North American Association of Central Cancer Registries 
as meeting high-quality incidence data standards for the specified time 
period. HPV-associated cancers are defined as cancers at specific ana-
tomic sites and with specific cellular types in which HPV DNA frequently 
is found. Some of these cancers may not necessarily be HPV-positive 
because no testing was conducted. White, black, Asian/Pacific Islander 
(API), and American Indian/Alaska Native (AI/AN) (IHS Contract Health 
Services Delivery Area counties) include Hispanic and non-Hispanic; the 
race and ethnicity categories are not mutually exclusive.
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Figure  3. Trends in age-adjusted human papillomavirus (HPV)–associ-
ated cancer incidence rates by sex and race and ethnicity in the United 
States, 2000 to 2009. An asterisk indicates average annual percent-
age change was statistically significantly different from zero at P less 
than .05. Trends could not be determined for American Indians/Alaska 
Natives (AI/ANs) for cancers of anus, vagina, vulva, and penis because of 
sparse data. The rates for the period from 2005 to 2009 for the five major 
racial and ethnic groups are from 42 states: Alabama, Alaska, Arizona, 
California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, 
Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, 
Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, 
Nevada, New Hampshire, New Jersey, New Mexico, New York, North 
Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South 
Carolina, Texas, Utah, Vermont, Washington, West Virginia, Wyoming. 
Source: National Program of Cancer Registries and Surveillance, 
Epidemiology, and End Results areas reported by the North American 
Association of Central Cancer Registries as meeting high-quality inci-
dence data standards for the specified time period. HPV-associated can-
cers are defined as cancers at specific anatomic sites and with specific 
cellular types in which HPV DNA frequently is found. Some of these can-
cers may not necessarily be HPV-positive because no testing was con-
ducted. White, black, Asian/Pacific Islander (API), and AI/AN (IHS Contract 
Health Services Delivery Area counties) include Hispanic and non-His-
panic; the race and ethnicity categories are not mutually exclusive.
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countries, including Denmark and Sweden (71–74). However, it is 
unclear why increases in HPV-associated oropharyngeal cancers in 
the United States are confined to white men and women. There are 
no data on the natural history of oral HPV infection or on changes 
in the prevalence of infection over time among the general popula-
tion or among oropharyngeal cancer patients by race and ethnicity.
Anal cancer incidence rates in the United States increased by 
more than twofold from 1975 to 2009 in both men and women 
(17), and the burden is higher among women than men. Among 
women, it is associated with an increasing number of sexual part-
ners, young age at first sexual intercourse, and sexually transmitted 
diseases, but most cases occur among those without a history of 
anal sex (75). Among men, one study found that men who have sex 
with men had the highest anal cancer incidence rates in California 
(76). A more recent US study (covering diagnosis years 1980 to 
2005) found that increases in anal cancer rates among men were 
largely influenced by the HIV epidemic (and driven primarily by 
increasing rates among HIV-positive men who have sex with men) 
(77). Increases in anal cancer incidence rates in Australia (78) and 
several European countries (79–81) were found to be associated 
with increases in high-risk sexual activities. In the United States, 
we also documented increases in incidence rates for cancers of the 
vulva among white and black women, and increases in these can-
cers (and anal cancer) may be due to increased sexual exposure to 
HPV (82).
In contrast to HPV-associated oropharyngeal and anal cancers, 
cervical cancer incidence rates declined substantially for women 
of most racial and ethnic groups because of wider dissemination 
and utilization of Pap testing and successful treatment of screen-
detected precancerous lesions (30–32), although the change for AI/
ANs was not statistically significant. The lack of decrease among 
AI/ANs and the substantially higher burden of cervical cancer 
among Hispanics may, in part, reflect issues regarding adherence 
to screening guidelines and other factors (83–85). According to 
national estimates from the 2010 NHIS, Asians and Hispanics 
women aged 21  years and older had a lower prevalence (75.4%, 
78.7%, respectively) of having had a Pap test in the past 3 years, 
compared with non-Hispanic blacks and non-Hispanic whites 
(85.0%, 83.4% respectively) (86). Racial disparities in cervical can-
cer rates may persist due to differences in screening, follow-up, and 
Figure 4. Three-dose human pappilomavirus (HPV) vaccination coverage among girls (aged 13 to 17 years), by state, in the United States, 2010. 
Source: National Immunization Survey-Teen (NIS-Teen) 2010, National Center for Health Statistics, Centers for Disease Control and Prevention, 2011. 
Girls in the 2010 NIS-Teen were born during the period from January 1992 to February 1998 and received either quadrivalent or bivalent human 
papillomavirus vaccine (some girls received more than three doses).
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Figure 5. Scatter plots of human pappilomavirus (HPV) vaccination cover-
age levels (A) and cervical cancer incidence rates (B) by Papanicolao (Pap) 
testing prevalence by state. P values were obtained by a two-sided t test. r, 
Pearson correlation coefficient. Three-dose HPV vaccination coverage lev-
els are reported for adolescent girls in the 2010 National Immunization 
Survey-Teen (NIS-Teen) who were born during the period from January 
1992 to February 1998. Girls may have received either quadrivalent or 
bivalent HPV vaccine. Source: National Immunization Survey-Teen 2008, 
2010, National Center for Health Statistics, Centers for Disease Control 
and Prevention, 2010, 2011. Five-year cervical cancer incidence rates dur-
ing the period from 2005 to 2009 for women aged 15 years or older are 
per 100,000 population and standardized to the 2000 US standard popu-
lation. States with missing rates did not meet North American Association 
of Central Cancer Registries (NAACCR) quality standards for the specified 
years and are not included in the reporting of incidence. Source: National 
Program of Cancer Registries and Surveillance, Epidemiology, and End 
Results Program reported by NAACCR as meeting high-quality incidence 
data standards for the specified time periods. Percentage of women aged 
21 to 65 years with intact uteri who received a Pap test in the previous 
3 years in 2010. Source: Behavioral Risk Factor Surveillance System Public 
Use Data Tape 2010, National Center for Chronic Disease Prevention and 
Health Promotion, Centers for Disease Control and Prevention, 2011.
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treatment of abnormal lesions (31,87,88). Cervical cancer remains 
a leading cause of cancer death among women in several economi-
cally developing countries because of lack of screening (89–91).
In 2006, the ACIP recommended routine vaccination of girls 
aged 11 to 12 years with the quadrivalent HPV vaccine and vac-
cination for unvaccinated girls and women aged 13 to 26  years 
(27). In 2009, when the bivalent vaccine was licensed in the United 
States, updated recommendations were issued to state that either 
vaccine should be used for routine vaccination and vaccination 
of previously unvaccinated women (28). According to NIS-Teen 
data, HPV vaccination uptake (one or more–dose, three-dose, and 
series completion rates) increased for adolescent girls of virtually 
all sociodemographic groups from 2008 to 2010, although not 
all increases were statistically significant. In 2010, less than half 
(48.7%) of girls aged 13 to 17 years had received one or more doses 
of vaccine, one in three girls (32.0%) received the entire three-
dose series, and 69.6% of those who initiated the series completed 
it (92). Nevertheless, the 2010 national three-dose coverage esti-
mate among girls aged 13 to 17 years (32%) falls well short of the 
Healthy People 2020 target of 80% for girls aged 13 to 15 years 
(93) and was much lower than uptake reported in Canada (50%–
85%), a region in Mexico (67%) (94), and the United Kingdom and 
Australia (>70%) (95,96). The low vaccine uptake in the United 
States overall and among socioeconomic disadvantaged groups is 
likely because of a combination of factors, including inadequate 
provider recommendations, issues regarding provider reimburse-
ment, infrequent use of reminder/recall systems that would foster 
completion of the three-dose series, and factors such as parental 
hesitancy, health-care access, and general challenges in vaccine 
delivery to adolescents (92,97–100).
Previous studies have found that health-care provider recom-
mendation is the most important predictor of vaccine acceptance 
(101–104). A  survey of pediatricians and family medicine physi-
cians conducted in 2008 (18 months after the initial licensure of the 
HPV vaccine) found that 57% strongly recommended vaccination 
for girls aged 11 to 12 years and 90% strongly recommended vacci-
nation for girls aged 13 to 15 years (102); another survey of primary 
care physicians in 2009 found only 34.6% “always recommended” 
vaccination to appropriately aged adolescent girls (105). Barriers 
to not “strongly or always” recommending vaccination included 
the need to discuss sexuality before recommending the vaccine; the 
high cost of the vaccine (approximately $390 for the three-dose 
series) and reimbursement concerns; parental refusal because of 
vaccine safety concerns, religious, or philosophical concerns; and 
lack of understanding of the HPV vaccine (102,106).
Although the vaccine is available free of cost through the VFC 
program for eligible children and adolescents (45), about 50% of 
surveyed physicians in 2008 reported inadequate insurance cover-
age and lack of adequate reimbursement as barriers to vaccination 
(102,107). Some states use state and/or local funding to purchase 
vaccine and offer it to children or adolescents not eligible for vac-
cine provided by the VFC program. With this additional funding, 
some states are able to provide vaccine to all children or adoles-
cents (ie, universal purchase policy), whereas some may only be 
able to provide vaccine to underinsured children. As of 2010, six 
states (New Hampshire, New Mexico, Rhode Island, Vermont, 
Washington, and Wyoming) had universal purchase policies that 
provided free HPV vaccine to all girls, including those who are 
VFC eligible, underinsured, and fully insured (108). Three-dose 
coverage rates in 2010 were higher than the national average 
(32%) for five of these six states, even though the national average 
included the six states with universal access. Other factors could 
also contribute to higher coverage in these states, including pro-
gram policies or activities that lead to higher coverage independent 
of the universal policy.
Patient reminder systems in primary care setting, such as tel-
ephone calls, postcards, and letters, have been shown to improve 
immunization rates (97,98), and have been recommended by the 
Task Force on Community Preventive Services (109) because many 
patients do not know or remember recommended immunization 
schedules. However, a 2008 survey of physicians found almost 
two-thirds of physicians did not use any reminder/recall system 
for patients needing a second or third dose of the HPV vaccine 
(102). Implementing such strategies may improve completion rates 
of three doses of the HPV vaccine in all girls, especially among 
VFC-eligible and uninsured girls, those living below the poverty 
level, and Hispanics, in whom the completion rates are the lowest.
Mandates that require immunization for school entry increase 
vaccination coverage levels for a number of childhood vaccines 
(110,111). Although many states mandate childhood (eg, measles, 
mumps, hepatitis B) and adolescent (eg, meningococcal conjugate, 
tetanus, diphtheria) immunization for school enrollment (112), only 
the District of Colombia and Virginia have school mandates for 
HPV vaccination (112,113). Notably, the 2010 national adolescent 
vaccination coverage for at least one dose of Tdap vaccine (tetanus, 
diphtheria, and acellular pertussis, 68.7%) (92), which was mandated 
by 31 states, was substantially higher than one-dose coverage for 
HPV vaccine (48.7%) (112,113). The initiation rates of HPV vac-
cination in the District of Colombia (57.5%) and Virginia (54.0%) 
are only slightly higher than the national average of 48.7%, likely 
because of broader opt-out provisions in the mandates for HPV 
vaccination than for other childhood and adolescent vaccinations.
Routine HPV vaccination of boys was recommended by the 
ACIP in December 2011 (29). Coverage in boys was only 1.4% 
in 2010 but will likely increase in the coming years, and this could 
substantially improve the overall herd immunity against HPV 
infection in view of the existing low vaccine uptake among ado-
lescent girls (92). Increasing current vaccination coverage levels 
among boys could eventually curb the growing burden of anal can-
cers, especially among men who have sex with men (76,114), and 
possibly the burden of oropharyngeal cancers.
Although HPV vaccination coverage among girls increased 
between 2008 and 2010 in most states, some Southern states con-
tinue to have lower HPV vaccination coverage. Pap testing preva-
lence is also low in these states, which show the highest cervical 
cancer burden in the United States. These unfavorable patterns 
may, at least in part, be because these areas are disproportionately 
represented by economically disadvantaged groups, including 
uninsured residents, blacks, and Hispanics (115), suggesting the 
need for focused cancer prevention and control in the region.
Limitations
High-quality cancer surveillance data in the United States are 
available for the entire population for mortality and for 93% of the 
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population for incidence (2005–2009); however, certain limitations 
in data sources, data collection, and analyses may have influenced 
the findings of this report. First, differences between the numera-
tor (incidence data) and denominator (Census population data) can 
occur in the designation of characteristics such as age, race, ethnic-
ity, and place of residency. Postcensal population estimates based 
on numbers updated by birth and death data, administrative infor-
mation, and emigration/immigration information are more sub-
ject to error than estimates based on actual Census counts; errors 
in these estimates may increase as time passes from the original 
recording of Census data. Additionally, the NCI modified these 
Census estimates to account for changes in 2005 county-level pop-
ulations due to displacement of people after Hurricanes Katrina 
and Rita in the most-affected counties of Louisiana, Mississippi, 
Alabama, and Texas.
Second, as noted in previous Annual Reports to the Nation (1–
14), the broad racial and ethnic groups categorized for our analyses 
may mask variations in the cancer burden by country of origin or 
by other unique characteristics of high- or low-risk populations. 
Also, cancer rates for racial and ethnic groups may be affected by 
difficulties in ascertaining race and ethnicity information from 
medical records, death certificates, and Census reports (116).
Third, analyses of trends should be carefully interpreted for 
several reasons. Changes in incidence may result from changes in 
the prevalence of risk factors, the introduction or increased use of 
screening or diagnostic techniques, or a combination of these. The 
AAPC was used as a summary measure to average trends over a 
5- or 10-year period using joinpoint regression; joinpoint models 
identify recent changes in the magnitude and direction of trends but 
may give an impression of a continuous increase or decrease over 
time when this is not the case. Furthermore, delayed case reporting 
may affect incidence trends if the most recent joinpoint segments 
overestimate recent declines or underestimate recent increases; 
methods to adjust for delayed reporting (53) were used only in 
the analysis of SEER 13 data. The largest effects of adjusting for 
delayed reporting are seen in cancers diagnosed in nonhospital set-
tings, such as melanoma and leukemia. This report presents trends 
based on both data from the SEER 13 registries and combined data 
from NAACCR, which includes SEER and NPCR registries. Both 
datasets have strengths and limitations and provide valuable insight 
into cancer trends in the United States. Longer-term trends can be 
examined using the SEER 13 registries, and these data have also 
been delay adjusted. However, the combined data from SEER and 
NPCR registries covers nearly the entire US population and may 
better capture geographic and population differences in risk factors 
and incidence.
Fourth, US Department of Veterans Affairs (VA) hospitals tra-
ditionally are a critical source of data for cancers diagnosed among 
veterans, representing approximately 3% to 8% of cancer diagno-
ses among men (117). A 2007 policy change regarding the trans-
fer of VA cancer data to central state cancer registries resulted in 
incomplete reporting of VA hospital cases in some, but not all, state 
registries, beginning in the third quarter of the 2004 diagnosis year 
through the current time period. However, with the enactment of 
special data-sharing agreements with the VA, progress in collect-
ing data from VA hospitals has been made, which resulted in more 
complete and accurate national cancer incidence estimates. As a 
result, the cancer incidence rates from 2005 to 2009 among men 
are underestimated by approximately 1% for all cancers combined, 
based on an analysis of data from the SEER registries, with slightly 
higher amounts (2%–4%) for rates among black men.
Fifth, we considered the cancers included in the special sec-
tion to be HPV-associated based on numerous rigorous etiologic 
studies and previously established methods (proportions of can-
cers generally found to be associated with HPV are listed in the 
Introduction) (20,118). However, specific information about the 
presence of HPV DNA in tumors was unavailable for this analy-
sis, and the number of HPV-associated cancers attributed to HPV 
infection should be cautiously interpreted because not all cancers 
termed “HPV-associated” reflect actual HPV infections.
Finally, both the BRFSS and NIS-Teen are landline telephone 
surveys and exclude households without landlines. The estimates 
from these surveys may be under- or overestimated, although they 
were adjusted for noncoverage of households with no landline tel-
ephones and for nonresponse (46,119). Generally, BRFSS respond-
ents tend to overreport behaviors that are considered desirable, such 
as screening (120). Therefore, the Pap test estimates from BRFSS 
(a self-reported survey) may have been overestimated. Further, 
estimates of Pap test and vaccination coverage for particular states 
and for racial and ethnic populations should be interpreted with 
caution because they may be unstable due to smaller sample sizes.
Future Directions
Although substantial progress in cancer prevention and control 
has been made for many cancers, including lung, colorectal, female 
breast, and prostate cancers (121), incidence and/or death rates 
continue to increase for some cancer sites (eg, liver, pancreas, kid-
ney, thyroid, and melanoma), underscoring the need for additional 
etiologic research for the identification of major risk factors and 
the development of appropriate interventions. Further, programs 
that increase uptake of proven cancer prevention strategies at the 
population level should be strengthened, along with broader access 
to early detection and treatment through increased access to the 
health-care system.
A greater understanding of the increasing incidence rates for 
HPV-associated cancers requires continued monitoring of changes 
in sexual practices that increase HPV exposure as well as of trends 
in the population-based prevalence of HPV infections at anatomic 
sites where these cancers arise. Notably, HPV-associated cancers 
occur in excess among people with HIV and AIDS relative to the 
general population, warranting additional monitoring and preven-
tion activities in this high-risk population (122–124).
Primary prevention of HPV-associated cervical, vaginal, vulvar, 
and anal cancers is achieved through childhood vaccination of girls 
and boys, although vaccine coverage remains low compared with 
the Healthy People 2020 target of 80% (93), and strategies are 
needed to increase coverage among adolescents. Educating health-
care workers about the importance of provider recommendation as 
an influential factor in a parent’s decision to allow HPV vaccination 
of their child may be the single most important way to increase 
coverage levels (101–104). Also, programs to educate parents 
about the importance of HPV vaccination as an anticancer vac-
cine and system changes, such as the implementation of automatic 
electronic reminders (for series completion) are also likely to be 
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important in increasing coverage (99). Increasing HPV vaccination 
coverage would also likely result in the added benefit of attaining 
levels of herd immunity observed in other countries (eg, Australia) 
and associated with decreased HPV transmission (125–127).
Research on HPV vaccines is ongoing in several areas. There 
is interest in evaluating the efficacy of less than three doses 
(128), and further data may be available on these schedules in 
the future. In addition, second-generation vaccines that target 
additional HPV types are being developed. Current data suggest 
good duration of protection afforded by the currently approved 
bivalent and quadrivalent vaccines, and ongoing studies will pro-
vide further data (129,130). Monitoring of vaccine safety is part 
of routine activities of the US Food and Drug Administration and 
the CDC, and current data are reassuring. A recent evaluation of 
quadrivalent HPV vaccine after the administration of more than 
600,000 doses in girls and women found no statistically signifi-
cant increased rate of prespecified adverse events (131). Safety 
monitoring of HPV vaccines will continue to investigate poten-
tial rare outcomes.
Early detection of cervical and noncervical cancers associated 
with HPV infection also deserves brief comment. For cervical 
cancers, the ACS and multiple clinical organizations, as well as the 
US Preventive Services Task Force, have recently issued updated 
age-specific guidelines for cytologic and HPV testing for the early 
detection of cervical cancer (30,31). These guidelines addressed 
critical issues about the harms of unnecessary procedures and 
treatments associated with transient HPV infections and associated 
cervical lesions, which regress without medical intervention. In 
addition, as HPV vaccination coverage levels increase, cervical can-
cer screening recommendations may need to be modified. The effi-
cacy of anal Pap testing to reduce mortality from HPV-associated 
anal cancer is unknown, and no national guidelines exist for anal 
cytology among men or women with or without HIV infection, 
although one study found it to be both clinically and cost effective 
to conduct such testing among HIV-positive gay and bisexual men 
(132,133).
As incidence rates for some HPV-associated cancers continue 
to rise, these cases will contribute to the overall growing num-
ber of cancers associated with population aging and expansion, 
requiring additional resources for medical research and treatment. 
Continued monitoring of incidence and mortality trends for all 
cancers is warranted to inform cancer prevention and control poli-
cies and programs.
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